This GLP-1 will act in the regulation of glucose metabolism, stimulating insulin secretion, while reducing glucagon secretion, thus reducing circulating glucose.15 However, in the prediabetic state, GLP-1 secretion is decreased, which impairs blood glucose control.16 Therefore, the detected 17% increase in GLP-1 in the blood serum of patients after treatment with Eriomin, associated with a 13% reduction in glucagon levels are pointed out as the likely causes of the decrease in hyperglycemia observed in this study. This evidence concerns the gene INS and Hyperglycemia.